Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease

Journal of the American Medical Directors Association

Volumn 18, Issue 12, 2017, Pages 1097.e11-1097.e24

  Smid, Dionne E ^a   Franssen, Frits M E ^a,b   Gonik, Maria ^c   Miravitlles, Marc ^d   Casanova, Ciro ^e   Cosio, Borja G ^f   de Lucas Ramos, Pilar ^g   Marin, Jose M ^h   Martinez, Cristina ⁱ   Mir, Isabel ^g   Soriano, Joan B ^j   de Torres, Juan P ^k   Agusti, Alvar ^l   Atalay, Nart B ^m   Billington, Julia ⁿ   Boutou, Afroditi K ^o,p   Brighenti Zogg, Stefanie ^q   Chaplin, Emma ^r   Coster, Samantha ^s   Dodd, James W ^t   Dürr, Selina ^q   Fernandez Villar, Alberto ^u   Groenen, Miriam T J ^a   Guimarães, Miguel ^v   Hejduk, Karel ^w   Higgins, Victoria ^x   Hopkinson, Nicholas S ^y   Horita, Nobuyuki ^z   Houben Wilke, Sarah ^a   Janssen, Daisy J A ^a   Jehn, Melissa ^aa   Joerres, Rudolf ^ab   Karch, Annika ^ac   Kelly, Julia L ^ad   Kim, Yu Il ^ae   Kimura, Hiroshi ^af   Koblizek, Vladimir ^ag   Kocks, Janwillem H ^ah   Kon, Samantha S C ^y,ai   Kwon, Namhee ^aj   Ladeira, Inês ^v   Lee, Sang Do ^ak   Leuppi, Joerg D ^q   Locantore, Nicholas ^al   Lopez Campos, José L ^am,an   D C Man, William ^y   Maricic, Lana ^ao   Mendoza, Laura ^ap   Miedinger, David ^q   Mihaltan, Florin ^aq   Minami, Seigo ^ar   van der Molen, Thys ^ah   Murrells, Trevor J ^s   Nakken, Nienke ^a   Nishijima, Yu ^ar,as   Norman, Ian J ^s   Novotna, Barbora ^ag   O'Donnell, Denis E ^at   Ogata, Yoshitaka ^ar   Pereira, Eanes D ^au   Piercy, James ^x   Price, David ^av,aw   Pothirat, Chaicharn ^ax   Raghavan, Natya ^ay   Ringbaek, Thomas ^az   Sajkov, Dimitar ^ba   Sigari, Naseh ^bb   Singh, Sally ^r   Small, Mark ^x   da Silva, Guilherme F ^bc   Tanner, Rebecca J ^y   Tsiligianni, Ioanna G ^ah,bd   Tulek, Baykal ^be   Tzanakis, Nikolaos ^bf   Vanfleteren, Lowie E G W ^a,b   Watz, Henrik ^bg   Webb, Katherine A ^at   Wouters, Emiel F M ^a,b   Xie, Guogang G ^bh   Yoshikawa, Masanori ^af   Spruit, Martijn A ^a,b,bi   more..

^a CIRO Center of Expertise for Chronic Organ Failure   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Biomax Informatics AG   (Germany)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^h HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

ⁱ HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^j HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^k UNIVERSITY CLINIC OF NAVARRA   (Spain)

^l UNIVERSITY OF BARCELONA   (Spain)

^m TOBB UNIVERSITY OF ECONOMICS AND TECHNOLOGY   (Turkey)

ⁿ Central Surgery Surbiton Health Centre   (United Kingdom)

^o GENERAL HOSPITAL   (Greece)

^p ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^q Kantonsspital Liestal   (Switzerland)

^r UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^s KING'S COLLEGE LONDON   (United Kingdom)

^t UNIVERSITY OF BRISTOL   (United Kingdom)

^u Instituto de Investigación Biomédica de Vigo   (Spain)

^v Hospital E P E   (Portugal)

^w MASARYK UNIVERSITY   (Czech Republic)

^x ADELPHI REAL WORLD   (United Kingdom)

^y ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^z YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^aa CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^ab LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^ac HANNOVER MEDICAL SCHOOL   (Germany)

^ad IMPERIAL COLLEGE LONDON   (United Kingdom)

^ae Chonnam National University Medical School   (South Korea)

^af NARA MEDICAL UNIVERSITY   (Japan)

^ag CHARLES UNIVERSITY   (Czech Republic)

^ah UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^ai Hillingdon Hospital NHS Trust   (United Kingdom)

^aj GLAXOSMITHKLINE   (United Kingdom)

^ak University of Ulsan College of Medicine   (South Korea)

^al GLAXOSMITHKLINE   (United States)

^am HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^an INSTITUTO DE SALUD CARLOS III   (Spain)

^ao UNIVERSITY HOSPITAL OSIJEK   (Croatia)

^ap HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^aq Marius Nasta Institute   (Romania)

^ar OSAKA POLICE HOSPITAL   (Japan)

^as OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^at KINGSTON GENERAL HOSPITAL   (Canada)

^au FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^av OBSERVATIONAL AND PRAGMATIC RESEARCH INSTITUTE   (Singapore)

^aw UNIVERSITY OF ABERDEEN   (United Kingdom)

^ax Faculty of Medicine Chiang Mai University   (Thailand)

^ay MCMASTER UNIVERSITY   (Canada)

^az UNIVERSITY OF COPENHAGEN   (Denmark)

^ba FLINDERS MEDICAL CENTRE   (Australia)

^bb KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^bc UNIVERSITY OF FORTALEZA   (Brazil)

^bd Agia Barbara Health Care Center   (Greece)

^be SELCUK UNIVERSITY   (Turkey)

^bf UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^bg GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^bh SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^bi HASSELT UNIVERSITY   (Belgium)

more..

Author keywords

clinical significance; COPD; GOLD; health status

Indexed keywords

BRONCHODILATING AGENT;

ADULT; AGE; AGED; ARTICLE; CALIBRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE BURDEN; DISEASE CLASSIFICATION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; SEX; SPIROMETRY; SYMPTOM; CLASSIFICATION; DISEASE EXACERBATION; EVIDENCE BASED MEDICINE; GLOBAL HEALTH; MIDDLE AGED; PRACTICE GUIDELINE; PROCEDURES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTOR; SICKNESS IMPACT PROFILE; SYMPTOM ASSESSMENT;

AGE FACTORS; AGED; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FEMALE; GLOBAL HEALTH; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SICKNESS IMPACT PROFILE; SYMPTOM ASSESSMENT;

EID: 85034568244     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2017.09.003     Document Type: Article

References (80)

1. Vogelmeier, C.F., Criner, G.J., Martinez, F.J., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. AJRCCM, 2017.
2. Jones, P.W., Adamek, L., Nadeau, G., et al. Comparisons of health status scores with MRC grades in COPD: Implications for the GOLD 2011 classification. Eur Respir J 42 (2013), 647–654.
3. Wilke, S., Smid, D.E., Spruit, M.A., et al. The 2014 updated GOLD strategy: A comparison of the various scenarios. JCOPDF 2 (2014), 212–220.
4. Casanova, C., Marin, J.M., Martinez-Gonzalez, C., et al. Differential effect of mMRC dyspnea, CAT and CCQ for symptom evaluation within the new GOLD staging and mortality in COPD. Chest 159 (2015), 159–168.
5. Holt, S., Sheahan, D., Helm, C., et al. Little agreement in GOLD category using CAT and mMRC in 450 primary care COPD patients in New Zealand. NPJ Prim Care Respir Med, 24, 2014, 14025.
6. Agusti, A., Hurd, S., Jones, P., et al. FAQs about the GOLD 2011 assessment proposal of COPD: A comparative analysis of four different cohorts. Eur Respir J 42 (2013), 1391–1401.
7. Lee, C.H., Lee, J., Park, Y.S., et al. Chronic obstructive pulmonary disease (COPD) assessment test scores corresponding to modified Medical Research Council grades among COPD patients. Korean J Intern Med 30 (2015), 629–637.
8. Tsiligianni, I.G., Alma, H.J., de Jong, C., et al. Investigating sensitivity, specificity, and area under the curve of the Clinical COPD Questionnaire, COPD Assessment Test, and Modified Medical Research Council scale according to GOLD using St George's Respiratory Questionnaire cutoff 25 (and 20) as reference. Int J Chron Obstruct Pulmon Dis 11 (2016), 1045–1052.
9. Kon, S.S., Canavan, J.L., Nolan, C.M., et al. The clinical chronic obstructive pulmonary disease questionnaire: Cut point for GOLD 2013 classification. Am J Respir Crit Care Med 189 (2014), 227–228.
10. Vogelmeier, C.F., Vestbo, J., Hurd, S.S., et al. Changes in GOLD: Today and tomorrow. Lancet Respir Med 3 (2015), 424–426.
11. Jones, P.W., Harding, G., Berry, P., et al. Development and first validation of the COPD Assessment Test. Eur Respir J 34 (2009), 648–654.
12. Pickard, A.S., Yang, Y., Lee, T.A., Comparison of health-related quality of life measures in chronic obstructive pulmonary disease. Health Qual Life Outcomes, 9, 2011, 26.
13. Youden, W.J., Index for rating diagnostic tests. Cancer 3 (1950), 32–35.
14. Lopez-Campos, J.L., Peces-Barba, G., Soler-Cataluna, J.J., et al. Chronic obstructive pulmonary disease history assessment in Spain: A multidimensional chronic obstructive pulmonary disease evaluation. Study methods and organization. Arch Bronconeumol 48 (2012), 453–459.
15. Price, D., West, D., Brusselle, G., et al. Management of COPD in the UK primary-care setting: An analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis 9 (2014), 889–904.
16. Jones, P.W., Nadeau, G., Small, M., et al. Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations. Resp Med 108 (2014), 129–135.
17. Vestbo, J., Vogelmeier, C., Small, M., et al. Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. Resp Med 108 (2014), 729–736.
18. da Silva, G.F., Morano, M.T., Sales, M.P., et al. Comparison of face-to-face interview and telephone interview administration of COPD assessment test: A randomized study. Qual Life Res 23 (2014), 1193–1197.
19. da Silva, G.P., Morano, M.T., Viana, C.M., et al. Portuguese-language version of the COPD Assessment Test: Validation for use in Brazil. J Bras Pneumol 39 (2013), 402–408.
20. Karch, A., Vogelmeier, C., Welte, T., et al. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Resp Med 114 (2016), 27–37.
21. Han, J., Dai, L., Zhong, N., Young, D., Breathlessness or health status in chronic obstructive pulmonary disease: The impact of different definitions. COPD 12 (2015), 115–125.
22. Grzelewska-Rzymowska, I., Patora-Mikolajczyk, J., Gorski, P., Stratification of patients with COPD according to the 2011 GOLD report. Pneumonologia i Alergologia Polska 82 (2014), 415–421.
23. Zhang, R., Tan, X., He, Q., et al. Comparison of symptom and risk assessment methods among patients with chronic obstructive pulmonary disease. Chin Med J 127 (2014), 2594–2598.
24. Paulin, L.M., Diette, G.B., Blanc, P.D., et al. Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 191 (2015), 557–565.
25. Gimeno-Santos, E., Raste, Y., Demeyer, H., et al. The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease. Eur Respir J 46 (2015), 988–1000.
26. Khurana, S., Ravi, A., Sutula, J., et al. Clinical characteristics and airway inflammation profile of COPD persistent sputum producers. Respir Med 108 (2014), 1761–1770.
27. Kurt, O.K., Tosun, M., Kurt, E.B., Talay, F., Pentraxin 3 as a novel biomarker of inflammation in chronic obstructive pulmonary disease. Inflammation 38 (2015), 89–93.
28. Dal Negro, R.W., Bonadiman, L., Turco, P., Sensitivity of the COPD assessment test (CAT questionnaire) investigated in a population of 681 consecutive patients referring to a lung clinic: The first Italian specific study. Multidiscip Respir Med, 9, 2014, 15.
29. Rieger-Reyes, C., Garcia-Tirado, F.J., Rubio-Galan, F.J., Marin-Trigo, J.M., Classification of chronic obstructive pulmonary disease severity according to the new Global Initiative for Chronic Obstructive Lung Disease 2011 guidelines: COPD assessment test versus modified Medical Research Council scale. Arch Bronconeumol 50 (2014), 129–134.
30. Hwang, Y.I., Jung, K.S., Lim, S.Y., et al. A Validation Study for the Korean Version of Chronic Obstructive Pulmonary Disease Assessment Test (CAT). Tuberc Respir Dis 74 (2013), 256–263.
31. Zhang, Y., Tu, Y.H., Fei, G.H., The COPD assessment test correlates well with the computed tomography measurements in COPD patients in China. Int J Chron Obstruct Pulmon Dis 10 (2015), 507–514.
32. Stoll, P., Ulrich, M., Bratke, K., et al. Imbalance of dendritic cell co-stimulation in COPD. Respir Res, 16, 2015, 19.
33. Nowak, C., Sievi, N.A., Clarenbach, C.F., et al. Accuracy of the hospital anxiety and depression scale for identifying depression in chronic obstructive pulmonary disease patients. Pulmon Med, 2014, 2014, 973858.
34. Lopes, A.J., Mafort, T.T., Correlations between small airway function, ventilation distribution, and functional exercise capacity in COPD patients. Lung 192 (2014), 653–659.
35. Ohno, T., Wada, S., Hanada, S., et al. Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences. Int J Chron Obstruct Pulmon Dis 9 (2014), 107–114.
36. Okutan, O., Tas, D., Demirer, E., Kartaloglu, Z., Evaluation of quality of life with the chronic obstructive pulmonary disease assessment test in chronic obstructive pulmonary disease and the effect of dyspnea on disease-specific quality of life in these patients. Yonsei Med J 54 (2013), 1214–1219.
37. Bai, P., Sun, Y., Jin, J., et al. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respir Res, 12, 2011, 157.
38. Zhou, Q.T., Mei, J.J., He, B., et al. Chronic obstructive pulmonary disease assessment test score correlated with dyspnea score in a large sample of Chinese patients. Chin Med J 126 (2013), 11–15.
39. Agusti, A., Soler-Cataluna, J.J., Molina, J., et al. Does the COPD assessment test (CAT(TM)) questionnaire produce similar results when self- or interviewer administered?. Qual Life Res 24 (2015), 2345–2354.
40. Billington, J., Coster, S., Murrells, T., Norman, I., Evaluation of a nurse-led educational telephone intervention to support self-management of patients with chronic obstructive pulmonary disease: A randomized feasibility study. COPD 12 (2015), 395–403.
41. Boutou, A.K., Tanner, R.J., Lord, V.M., et al. An evaluation of factors associated with completion and benefit from pulmonary rehabilitation in COPD. BMJ Open Respir Res, 1, 2014, e000051.
42. de Torres, J.P., Marin, J.M., Martinez-Gonzalez, C., et al. Clinical application of the COPD assessment test: Longitudinal data from the COPD History Assessment in Spain (CHAIN) cohort. Chest 146 (2014), 111–122.
43. Casanova, C., Marin, J.M., Martinez-Gonzalez, C., et al. New GOLD classification: Longitudinal data on group assignment. Respir Res, 15, 2014, 3.
44. Chaplin, E., Gibb, M., Sewell, L., Singh, S., Response of the COPD Assessment Tool in stable and postexacerbation pulmonary rehabilitation populations. J Cardiopulmon Rehabil Prevent 35 (2015), 214–218.
45. Dodd, J.W., Hogg, L., Nolan, J., et al. The COPD assessment test (CAT): Response to pulmonary rehabilitation. A multicentre, prospective study. Thorax 66 (2011), 425–429.
46. Horita, N., Yomota, M., Sasaki, M., et al. Evaluation of the chronic obstructive pulmonary disease assessment test in Japanese outpatients. Clin Respir J, 2013.
47. Jehn, M., Donaldson, G., Kiran, B., et al. Tele-monitoring reduces exacerbation of COPD in the context of climate change–A randomized controlled trial. Environ Health, 12, 2013, 99.
48. Kelly, J.L., Bamsey, O., Smith, C., et al. Health status assessment in routine clinical practice: The chronic obstructive pulmonary disease assessment test score in outpatients. Respiration 84 (2012), 193–199.
49. Kim, S., Oh, J., Kim, Y.I., et al. Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: A cross-sectional analyses. BMC Pulmon Med, 13, 2013, 35.
50. Kon, S.S., Dilaver, D., Mittal, M., et al. The Clinical COPD Questionnaire: Response to pulmonary rehabilitation and minimal clinically important difference. Thorax 69 (2014), 793–798.
51. Kwon, N., Amin, M., Hui, D.S., et al. Validity of the COPD assessment test translated into local languages for Asian patients. Chest 143 (2013), 703–710.
52. Lee, S.D., Huang, M.S., Kang, J., et al. The COPD assessment test (CAT) assists prediction of COPD exacerbations in high-risk patients. Respir Med 108 (2014), 600–608.
53. Ladeira, I., Gomes, T., Castro, A., et al. The overall impact of COPD (CAT) and BODE index on COPD male patients: Correlation?. Revista Portuguesa de Pneumologia 21 (2015), 11–15.
54. Lopez-Campos, J.L., Fernandez-Villar, A., Calero-Acuna, C., et al. Evaluation of the COPD Assessment Test and GOLD patient types: A cross-sectional analysis. Int J Chron Obstruct Pulmon Dis 10 (2015), 975–984.
55. Manca, S., Rodriguez, E., Huerta, A., et al. Usefulness of the CAT, LCOPD, EQ-5D and COPDSS scales in understanding the impact of lung disease in patients with alpha-1 antitrypsin deficiency. COPD 11 (2014), 480–488.
56. Maricic, L., Vceva, A., Visevic, R., et al. Assessment of endothelial dysfunction by measuring von Willebrand factor and exhaled nitric oxide in patients with chronic obstructive pulmonary disease. Collegium antropologicum 37 (2013), 1153–1160.
57. Mendoza, L., Horta, P., Espinoza, J., et al. Pedometers to enhance physical activity in COPD: A randomised controlled trial. Eur Respir J, 2015, 45347–45354.
58. Mihaltan, F., “Inspirom”–Overview of the relationship between the pulmonologist and the COPD patient in Romania. Pneumologia 64 (2015), 24–28.
59. Miravitlles, M., Barrecheguren, M., Roman-Rodriguez, M., Frequency and characteristics of different clinical phenotypes of chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 19 (2015), 992–998.
60. Miravitlles, M., Molina, J., Quintano, J.A., et al. Factors associated with depression and severe depression in patients with COPD. Respir Med 108 (2014), 1615–1625.
61. Minami, S., Yamamoto, S., Ogata, Y., et al. Ambulatory pulse oximetry monitoring in Japanese COPD outpatients not receiving oxygen therapy. Multidisciplinary Respir Med, 9, 2014, 24.
62. Nakken, N., Janssen, D.J., van den Bogaart, E.H., et al. An observational, longitudinal study on the home environment of people with chronic obstructive pulmonary disease: The research protocol of the Home Sweet Home study. BMJ Open, 4, 2014, e006098.
63. Nishijima, Y., Minami, S., Yamamoto, S., et al. Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 10 (2015), 439–444.
64. Novotna, B., Koblizek, V., Zatloukal, J., et al. Czech multicenter research database of severe COPD. Int J Chron Obstruct Pulmon Dis 9 (2014), 1265–1274.
65. Pothirat, C., Kiatboonsri, S., Chuchottaworn, C., Validation of the new COPD assessment test translated into Thai in patients with chronic obstructive pulmonary disease. BMC Pulmon Med, 14, 2014, 193.
66. Pothirat, C., Chaiwong, W., Phetsuk, N., et al. Dialectal influence on chronic pulmonary disease assessment test: The reliability and validity study. Int J Chron Obstruct Pulmon Dis 10 (2015), 541–548.
67. Price, D.B., Baker, C.L., Zou, K.H., et al. Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification. Int J Chron Obstruct Pulmon Dis 9 (2014), 551–561.
68. Raghavan, N., Lam, Y.M., Webb, K.A., et al. Components of the COPD Assessment Test (CAT) associated with a diagnosis of COPD in a random population sample. COPD 9 (2012), 175–183.
69. Ringbaek, T., Martinez, G., Lange, P., A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation. COPD 9 (2012), 12–15.
70. Sigari, N., Moghimi, N., Shahraki, F.S., et al. Anti-cyclic citrullinated peptide (CCP) antibody in patients with wood-smoke-induced chronic obstructive pulmonary disease (COPD) without rheumatoid arthritis. Rheumatol Int 35 (2015), 85–91.
71. Tsiligianni, I.G., van der Molen, T., Moraitaki, D., et al. Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ). BMC Pulmon Med, 12, 2012, 20.
72. Tulek, B., Atalay, N.B., Yildirim, G., et al. Cognitive function in chronic obstructive pulmonary disease: Relationship to global initiative for chronic obstructive lung disease 2011 categories. Respirology 19 (2014), 873–880.
73. Xie, G., Zhang, Y., Zhou, X., New disease severity classification of patients with stable chronic obstructive pulmonary disease in Shanghai. Chin Med J 127 (2014), 3046–3050.
74. Yoshikawa, M., Fujita, Y., Yamamoto, Y., et al. Mini-Nutritional Assessment Short-Form predicts exacerbation frequency in patients with chronic obstructive pulmonary disease. Respirology 19 (2014), 1198–1203.
75. Zogg, S., Durr, S., Miedinger, D., et al. Differences in classification of COPD patients into risk groups A-D: A cross-sectional study. BMC Res Notes, 7, 2014, 562.
76. Woodruff, P.G., Barr, R.G., Bleecker, E., et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 374 (2016), 1811–1821.
77. Sillen, M.J., Franssen, F.M., Delbressine, J.M., et al. Heterogeneity in clinical characteristics and comorbidities in dyspneic individuals with COPD GOLD D: Findings of the DICES trial. Resp Med 107 (2013), 1186–1194.
78. Wilke, S., Jones, P.W., Mullerova, H., et al. One-year change in health status and subsequent outcomes in COPD. Thorax 70 (2015), 420–425.
79. Buist, A.S., McBurnie, M.A., Vollmer, W.M., et al. International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study. Lancet 370 (2007), 741–750.
80. Janssen, D.J., Spruit, M.A., Uszko-Lencer, N.H., et al. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med 14 (2011), 735–743.